CRISPR Therapeutics’ Post

Did you know that our model has a naturally low prevalence of circulating Nabs to AAVs? This means less subjects screened for inclusion, saving time, money and supporting the 3Rs. Come see us at booth 814 to learn more. Check out the link for more information! #AAV #research #scientificadvancements #virscio #ASCGT #cellandgenetherapy

Heading to ASGCT in Baltimore? Come get your groove on at booth #730 or check out our talk to learn how Stunner and Leprechaun can help you bust through bottlenecks in your gene and cell therapy workflows! #ASGCT2024!

Read about the technological and clinical hurdles facing CAR T-cell therapies and their application to solid tumors. See how high-throughput assays provide a cost-effective route for developing safer and more effective CAR T-cell therapies. What you'll learn from Progress in Challenges In Developing CAR T-Cell Therapies: -Why to track CAR T-cell responses with flow cytometry -When to use ddPCR™ for CAR gene quality control -How to minimize CAR T-cell therapy side effects Access article: http://ow.ly/FhaV50NOEs8

新增一批生物药和CGT研发职位（Antibody Discovery，Biology，immune-oncology， cell therapy process，cell therapy Discovery，AAV gene therapy Discovery，DMPK）https://lnkd.in/gVFt2Hj5

Thank you Lung-I Cheng for facilitating this robust discussion at Reuters Events Pharma about the value of #patient engagement in #cell and #gene therapy development. Key takeaways included: *Innovative study designs, such as leveraging #RWE, is needed to develop treatments for rare diseases which often have small patient populations. *Leveraging information from #FDA's patient focused drug development meetings is important to understanding the patient experience. *The rapid development of #CGTs is a paradigm shift for many regulating bodies, and risk-based flexability is needed to ensure timely #patient #access. *Long-term patient follow up remains a challenge, but the value of capturing patient #data remains a priority. Fellow Panelists: Olga Granaturova, Co-founder, President, PriveBio Jeffrey Meckler, Chief Executive Officer, Indaptus Therapeutics Jason Lott, MD MSHP MHS FAAD, VP, Global Integrated Evidence Generation, Specialty Medicine, Integrated Care, and Cell-Gene Therapy, Bayer Special thanks to my colleagues American Society of Gene & Cell Therapy for supporting my participation at events on this important topic. #ASGCT #ASGCTadvocacy #CellTherapy #GeneTherapy

Get the latest on pediatric cell and gene clinical research in this webinar hosted by Institute for Advanced Clinical Trials for Children (I-ACT for Children) on June 25. Advarra's Daniel Eisenman PhD, CBSP will share his biosafety insights with the panel. #clinicaltrials #celltherapy #genetherapy

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

Want to hear more about negotiating cell and gene therapy deals? We’ve got a great panel line up on 5 June so do sign up to hear more about their experiences when CGT licensing and collaboration agreements, investment rounds and more. I’m really looking forward to chairing this discussion! 😀🧬🏥 #bristowsllp, #onenucleus, #cellandgene, #intellectualproperty, #lifesciences